eConsent Solutions
-
Full Visibility For Study Teams And Control Over Consent
9/16/2025
Enhancing patient comprehension and giving study teams full visibility and control over consent throughout your trial.
-
How Can Phase 1 Trials Employ eClinical Solutions?
1/8/2024
Uncover how this unified platform is helping sponsors and CROs generate high-quality data, accelerate trials, and rapidly scale to Phase 2 and beyond.
-
Better Experiences And Faster Startups
8/22/2022
By combining electronic form workflows and interactive question-and-answer sections, this eConsent solution optimizes ICF processes to offer improved patient and user experiences.
-
End-To-End Digital Therapeutics Studies Powered By Technology
2/2/2023
Curebase offers a variety of decentralized study models designed and tested for any type of DTx trial.
-
A Modern Clinical Research Platform
4/17/2025
Explore a platform supporting secure integration of real-world data (RWD) from EHRs and tokenization, enabling rich, longitudinal insights, and flexible study designs.
-
Just The Facts: Direct Data Capture
5/20/2022
Start enabling direct data capture (DDC), clinical outcome assessments (eCOA), patient reported outcomes (ePRO), and eConsent with the Clinical ink platform.
-
Electronic Informed Consent For Clinical Research
2/16/2024
We partnered with leading academic medical centers, sponsors, hospital systems, and site networks to create an eConsent platform that is easy-to-use and minimizes risk.
-
Unlock Additional Capabilities For Your Next Clinical Trial
2/21/2023
Gain insight on how a single point of entry can improve patient and site experience by offering best-in-class eCOA, consent management, and patient engagement solutions.
-
The Path To Proof, Reimagined
5/15/2024
By combining technology with clinical and operational expertise, Signant Health prioritizes the clinical research stakeholder experience, making it more intuitive, while ensuring the data journey is direct.
-
Hybrid eConsent: Remote And On-Site
3/21/2025
Studies show when participants are informed and comfortable with the consent process, they're more likely to comply with protocol, remain enrolled, and contribute to faster study deployment.